MRI Interventions Named 2012 Global Company of the Year in Image-Guided Neural Interventions

MRI Interventions Named 2012 Global Company of the Year in Image-Guided Neural

PR Newswire

MEMPHIS, Tenn., Nov. 27, 2012

MEMPHIS, Tenn., Nov. 27, 2012 /PRNewswire/ --MRI Interventions, Inc. (OTCBB:
MRIC), a commercial stage medical device company focused on creating
innovative platforms for performing the next generation of minimally invasive
surgical procedures in the brain and heart, announced today that it has been
presented the 2012 Global Company of the Year Award in Image-Guided Neural
Interventions by Frost & Sullivan, a global business research and consulting
firm. The award criteria established by Frost & Sullivan included degree of
innovation with products and technologies, growth strategy excellence, growth
implementation excellence, and leadership in customer value. Based on its own
best practice research with industry value chain players, Frost & Sullivan
concluded that MRI Interventions outperformed its competitors with respect to
every award criterion.

MRI Interventions' innovative product, the ClearPoint® system, provides an
integrated platform for performing a range of minimally-invasive neurological
procedures under direct, real-time magnetic resonance imaging (MRI) guidance.
ClearPoint is an integrated system of reusable components, disposable
components and intuitive menu-driven software, which provides guidance for the
placement and operation of instruments during neurological procedures
performed within the MRI environment. Using the ClearPoint system, a surgeon
sees and selects a neurological target, aims the ClearPoint targeting device,
and watches in real-time as the surgical instrument is advanced to the

"MRI Interventions' ClearPoint system enables neurological interventions which
offer distinct advantages over conventional and robotic procedures," said
Frost & Sullivan healthcare industry analyst Beulah Devadason. "The many
advantages of this system include reduced patient trauma, and reduction in the
overall cost and time required for procedures, which further improves
profitability for hospitals."

To date, ClearPoint systems have been installed at 16 hospitals in the United
States and two hospitals in Europe. ClearPoint systems are in clinical use in
connection with MRI scanners from the three major MRI scanner manufacturers,
Siemens, GE Healthcare and Philips Healthcare, as well as the two major
interventional MR/OR platforms that are manufactured by IMRIS and Brainlab.

"We are honored to accept the 2012 Company of the Year Award in Image-Guided
Neural Interventions from such a well-respected organization," said Kimble
Jenkins, MRI Interventions' CEO. "This kind of industry recognition is welcome
validation that our team's hard work in developing and bringing to market the
ClearPoint system is paying off." In 2010, the magazine Medical Device +
Diagnostic Industry named MRI Interventions (then known as SurgiVision) as one
of the 50 companies to watch in the medical device industry.

About MRI Interventions, Inc.

Founded in 1998, MRI Interventions is creating innovative platforms for
performing the next generation of minimally invasive surgical procedures in
the brain and heart. Utilizing a hospital's existing MRI suite, the company's
FDA-cleared ClearPoint® system is designed to enable a range of minimally
invasive procedures in the brain. MRI Interventions has a co-development and
co-distribution agreement with Brainlab, a leader in software-driven medical
technology, relating to the ClearPoint system. In partnership with Siemens
Healthcare, MRI Interventions is developing the ClearTrace™ system to enable
MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial
fibrillation. Building on the imaging power of MRI, the company's
interventional platforms strive to improve patient care while reducing
procedure costs and times. MRI Interventions is also working with Boston
Scientific Corporation to incorporate its MRI-safety technologies into Boston
Scientific's implantable leads for cardiac and neurological applications. For
more information, please visit

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
CEO's Growth Team with disciplined research and best-practice models to drive
the generation, evaluation and implementation of powerful growth strategies.
Frost & Sullivan leverages 50 years of experience in partnering with Global
1000 companies, emerging businesses and the investment community from more
than 40 offices on six continents. For more information, please visit

Forward-Looking Statements

Certain matters in this press release may constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking statements
often can be identified by words such as "anticipates," "believes," "could,"
"estimates," "expects," "intends," "may," "plans," "potential," "predicts,"
"projects," "should," "will," "would," or the negative of these words or other
words of similar meaning. Forward-looking statements by their nature address
matters that, to different degrees, are uncertain and involve risk.
Uncertainties and risks may cause MRI Interventions' actual results and the
timing of events to differ materially from those expressed in or implied by
MRI Interventions' forward-looking statements. Particular uncertainties and
risks include, among others: demand and market acceptance of our products; our
ability to successfully expand our sales and marketing capabilities; our
ability to successfully complete the development of, and to obtain regulatory
clearance or approval for, future products, including our current product
candidates; availability of third party reimbursement; the sufficiency of our
cash resources to maintain planned commercialization efforts and research and
development programs; future actions of the FDA or any other regulatory body
that could impact product development, manufacturing or sale; our ability to
protect and enforce our intellectual property rights; our dependence on
collaboration partners; the impact of competitive products and pricing; and
the impact of the commercial and credit environment on us and our customers
and suppliers. More detailed information on these and additional factors that
could affect MRI Interventions' actual results are described in MRI
Interventions' filings with the Securities and Exchange Commission, including,
without limitation, the quarterly report on Form 10-Q for the quarterly period
ended September 30, 2012.Except as required by law, MRI Interventions
undertakes no obligation to publicly update or revise any forward-looking
statements contained in this press release to reflect any change in MRI
Interventions' expectations or any change in events, conditions or
circumstances on which any such statements are based.

MRI Interventions, Inc.
David Carlson, CFO, 901.522.9300

SOURCE MRI Interventions, Inc.

Press spacebar to pause and continue. Press esc to stop.